2026
01/27/26 – Epirium Bio Announces Positive Outcome of Type C FDA Meeting
2025
11/17/25 – Epirium Bio Presented Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data for MF-300 at GSA Scientific Meeting 2025
09/24/25 – Epirium Bio Announces Positive Phase 1 Clinical Trial Results Evaluating MF-300 in Healthy Volunteers
07/21/25 – Epirium Bio Completes Dosing in First in Human Phase 1 Clinical Trial Evaluating MF-300 A First In-Class Oral 15-PDGH Enzyme Inhibitor for the Treatment of Sarcopenia
03/13/25 – Epirium Bio to Present MF-300 Preclinical Data at the International Conference on Frailty and Sarcopenia Research
01/30/25 – Epirium Bio Announces First Participants Dosed in Phase I Clinical Trial Evaluating MF-300 for the Treatment of Sarcopenia
2024
12/23/24 – Epirium Bio Announces FDA Clearance of IND Application for MF-300 and Appointment of Alex Casdin as New CEO and Russell Cox as Executive Chairman
11/13/24 – Epirium Bio Presented Late-Breaking Preclinical Data of MF-300 (15-PGDH Enzyme Inhibitor) at the Gerontological Society of America Annual Scientific Meeting 2024